Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465750 | 0.88 | TSHR (0.33) | CTRCTDP1 | |
| Propane SCHEMBL28903031 | 0.83 | TDP1 (0.32) | TDP1 | |
| Butane SCHEMBL29290122 | 0.83 | TDP1 (0.32) | TDP1 | |
| Alcohol SCHEMBL8524158 | 0.80 | ALDH1A1 (0.40) | TDP1 | |
| Alcohol SCHEMBL28609609 | 0.78 | ALDH1A1 (0.38) | — | |
| Ethyne SCHEMBL10357623 | 0.70 | — | — | |
| SCHEMBL687192 | 0.67 | — | — | |
| Acetic Acid SCHEMBL11212519 | 0.65 | FFAR3 (0.44) | TDP1 | |
| Ethyl Chloride SCHEMBL1331853 | 0.63 | — | — | |
| Ethyl Chloride SCHEMBL20021 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638535-B2 | (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-7635706-B2 | 1-butyl-3-hydroxy4-piperidinyl)methyl 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylate and chemical intermediates; treating hypermotility, irritable bowel syndrome (IBS) constipation or diarrhea predominant IBS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-22 | — | — | US | disclosed |
| EP-1638959-B1 | 5HT -4 -ANTAGONISTIC 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES | JANSSEN PHARMACEUTICA NV (BE) | 2007-09-19 | — | — | EP | disclosed |
| EP-1641784-B1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4 -ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-20070032486-A1 | 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-20060281753-A1 | 4-(Aminomethyl)-piperidine benzamides as 5ht4 - antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| EP-1641784-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4 -ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1638959-A1 | 5HT -4 -ANTAGONISTIC 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005003122-A1 | 5HT4-ANTAGONISTIC 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005000838-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032486-A1 | 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides | HTR4, HTR2B, TPH2 | CTRC 4305/4885TDP1 4125/4885 |
| US-20060281753-A1 | 4-(Aminomethyl)-piperidine benzamides as 5ht4 - antagonists | HTR4, HTR2B, HTR5A | CTRC 4174/4885TDP1 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.